Lupin receives EIR from USFDA for Pithampur Unit-1 facility

30 Apr 2020 Evaluate
Lupin has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Pithampur Unit-1, India facility. The inspection for the facility was conducted by the USFDA between February 3, 2020 and February 11, 2020 and concluded with two observations.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2151.05 19.25 (0.90%)
30-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1595.00
Dr. Reddys Lab 1218.40
Cipla 1323.95
Zydus Lifesciences 885.20
Lupin 2151.05
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×